MP 101 - Mitochon Pharmaceuticals

Drug Profile

MP 101 - Mitochon Pharmaceuticals

Alternative Names: MP101 - Mitochon Pharmaceuticals

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitochon Pharmaceuticals
  • Class Antiepileptic drugs; Neuroprotectants; Small molecules
  • Mechanism of Action Brain-derived neurotrophic factor expression modulators; Mitochondrial protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy; Epilepsy; Huntington's disease

Most Recent Events

  • 08 Nov 2017 Mitochon Pharmaceuticals receives patent allowance for MP 101 in USA
  • 06 Oct 2017 Pharmacodynamics data from a preclinical trial in Huntington's disease released by Mitochon Pharmaceuticals
  • 06 Oct 2017 Preclinical trials in Duchenne muscular dystrophy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top